What is your preferred first line treatment approach for a patient with PDL-1 high (>50%) NSCLC presenting with CNS mets?
2 Answers
Mednet Member
Medical Oncology · Karmanos Cancer Institute, Wayne State University
The treatment decision and sequencing in patients with brain metastasis from non-oligometastatic NSCLC with high PD-L1 expression and no traditional actionable genomic alterations depend on size and location of brain mets as well as associated symptoms.
Based on data from several prospective and retr...